{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:55:04Z","timestamp":1775602504977,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glucose-lowering medications with established reno-protective effects are still underused in Italy. We explored whether attending an integrated nephrology and diabetology (NPD) outpatient service can improve clinical outcomes and adherence to treatment guidelines for diabetic kidney disease (DKD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively included 110 DKD patients (aged 71.1\u2009\u00b1\u200910.1 years; 74.5% males) having attended the NPD outpatient service of CTO Hospital (Rome) between June and November 2023. Age- and gender-matched control group included DKD patients attending regular Diabetology outpatient service. Drugs prescriptions, clinical and biochemical parameters related to routine evaluation of DKD were collected at first and 6-months control visit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This DKD population was made of 28.2% of patients with urine albumin-creatinine ratio (UACR)\u2009&gt;\u200930\u00a0mg\/gr, 33.6% with glomerular filtration rate (GFR)\u2009&lt;\u200960\u00a0ml\/min, 38.2% with both abnormalities. Proportion of patients prescribed with most recent anti-diabetic medications significantly increased after attending the NPD service (for SGLT-2 inhibitors, 54.5 vs. 25.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01; for GLP1-R agonists, 28.3 vs. 21.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.01), as well as for statins (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and calcium channel-blockers (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). During the same observation period we registered significant reduction in LDL cholesterol (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) and UACR levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), with a trend toward improvement in HbA1c and eGFR. Conversely, no significant differences in drugs prescriptions were reported in the control group, except for SGLT-2 inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Enhanced real-time interaction and collaborative decision-making in an outpatient setting that integrates both diabetology and nephrology expertise can lead to better clinical outcomes and greater adherence to DKD management guidelines, ultimately providing a more comprehensive strategy for cardio-renal risk reduction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00592-024-02423-w","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:45:12Z","timestamp":1740131112000},"page":"1057-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Attending an integrated nephrology and diabetology outpatient service can improve diabetic kidney disease treatment: a single-center experience"],"prefix":"10.1007","volume":"62","author":[{"given":"S. Wolde","family":"Sellasie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pecchioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cersosimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zaccaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Centi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Di Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tatangelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Giurato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-4622","authenticated-orcid":false,"given":"A.","family":"Bellia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Uccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"2423_CR1","doi-asserted-by":"publisher","unstructured":"Rossing P et al (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int 102(5):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"2423_CR2","doi-asserted-by":"publisher","unstructured":"Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and, treatment. Biomed Res Int 2021:1\u201317. https:\/\/doi.org\/10.1155\/2021\/1497449","DOI":"10.1155\/2021\/1497449"},{"key":"2423_CR3","doi-asserted-by":"publisher","unstructured":"Doshi SM, Friedman AN (2017) Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol 12(8):1366\u20131373. https:\/\/doi.org\/10.2215\/CJN.11111016","DOI":"10.2215\/CJN.11111016"},{"key":"2423_CR4","doi-asserted-by":"publisher","unstructured":"Wei H, Ren J, Li R, Qi X, Yang F, Li Q (2024) Global, regional, and national burden of chronic kidney disease attributable to high fasting plasma glucose from 1990 to 2019: a systematic analysis from the global burden of disease study 2019. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2024.1379634","DOI":"10.3389\/fendo.2024.1379634"},{"key":"2423_CR5","doi-asserted-by":"publisher","unstructured":"Lee H-J, Son Y-J (2021) Prevalence and associated factors of frailty and mortality in patients with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis. Int J Environ Res Public Health 18(7):3471. https:\/\/doi.org\/10.3390\/ijerph18073471","DOI":"10.3390\/ijerph18073471"},{"key":"2423_CR6","doi-asserted-by":"publisher","unstructured":"Pugliese G (2014) Updating the natural history of diabetic nephropathy. Acta Diabetol 51(6):905\u2013915. https:\/\/doi.org\/10.1007\/s00592-014-0650-7","DOI":"10.1007\/s00592-014-0650-7"},{"key":"2423_CR7","doi-asserted-by":"publisher","unstructured":"Orchard TJ, Secrest AM, Miller RG, Costacou T (2010) In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 53(11):2312\u20132319. https:\/\/doi.org\/10.1007\/s00125-010-1860-3","DOI":"10.1007\/s00125-010-1860-3"},{"key":"2423_CR8","doi-asserted-by":"publisher","unstructured":"Wu H-Y et al (2017) Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study. PLoS ONE 12(5):e0177654. https:\/\/doi.org\/10.1371\/journal.pone.0177654","DOI":"10.1371\/journal.pone.0177654"},{"key":"2423_CR9","doi-asserted-by":"publisher","unstructured":"Cherney DZI, Bakris GL (2018) Novel therapies for diabetic kidney disease. Kidney Int Suppl (2011) 8(1):18\u201325. https:\/\/doi.org\/10.1016\/j.kisu.2017.10.005","DOI":"10.1016\/j.kisu.2017.10.005"},{"key":"2423_CR10","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY, Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"2423_CR11","doi-asserted-by":"publisher","unstructured":"Heerspink HJL et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):743\u2013754. https:\/\/doi.org\/10.1016\/S2213-8587(21)00242-4","DOI":"10.1016\/S2213-8587(21)00242-4"},{"key":"2423_CR12","doi-asserted-by":"publisher","unstructured":"Russo G et al (2023) The AMD ANNALS: a continuous initiative for the improvement of type 2 diabetes care. Diabetes Res Clin Pract 199:110672. https:\/\/doi.org\/10.1016\/j.diabres.2023.110672","DOI":"10.1016\/j.diabres.2023.110672"},{"key":"2423_CR13","doi-asserted-by":"publisher","unstructured":"Nelson AJ et al (2022) Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Netw Open 5(2):e2148030. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48030","DOI":"10.1001\/jamanetworkopen.2021.48030"},{"key":"2423_CR14","doi-asserted-by":"publisher","unstructured":"Boyd CT, Spangler JG, Strickland CG, Roper JE, Kirk JK (2023) Impact of group medical visits on patient engagement and quality of life. Expert Rev Endocrinol Metab 18(6):549\u2013554. https:\/\/doi.org\/10.1080\/17446651.2023.2268716","DOI":"10.1080\/17446651.2023.2268716"},{"key":"2423_CR15","doi-asserted-by":"publisher","unstructured":"Mannucci E et al (2023) 2023 update on Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol 60(8):1119\u20131151. https:\/\/doi.org\/10.1007\/s00592-023-02107-x","DOI":"10.1007\/s00592-023-02107-x"},{"key":"2423_CR16","doi-asserted-by":"publisher","unstructured":"Marx N et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"2423_CR17","doi-asserted-by":"publisher","unstructured":"Pagidipati NJ et al (2023) Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes. JAMA 329:1261. https:\/\/doi.org\/10.1001\/jama.2023.2854","DOI":"10.1001\/jama.2023.2854"},{"key":"2423_CR18","doi-asserted-by":"publisher","unstructured":"Stevens PE, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","DOI":"10.7326\/0003-4819-158-11-201306040-00007"},{"key":"2423_CR19","doi-asserted-by":"publisher","unstructured":"Couser WG, Remuzzi G, Mendis S, Tonelli M (2011) The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 80(12):1258\u20131270. https:\/\/doi.org\/10.1038\/ki.2011.368","DOI":"10.1038\/ki.2011.368"},{"key":"2423_CR20","doi-asserted-by":"publisher","unstructured":"Penno G et al (2018) Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study, Diabetologia 61(11):2277\u20132289. https:\/\/doi.org\/10.1007\/s00125-018-4691-2","DOI":"10.1007\/s00125-018-4691-2"},{"key":"2423_CR21","doi-asserted-by":"publisher","unstructured":"Tanr\u0131verdi M, Ba\u015ftemir M, Demirbakan H, \u00dcnalan A, T\u00fcrkmen M, Tanr\u0131verdi G\u00d6 (2023) Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocr Disord 23(1):211. https:\/\/doi.org\/10.1186\/s12902-023-01464-6","DOI":"10.1186\/s12902-023-01464-6"},{"key":"2423_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","author":"V Perkovic","year":"2024","unstructured":"Perkovic V et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"New Engl J Med May"},{"key":"2423_CR23","doi-asserted-by":"publisher","unstructured":"Tunnicliffe DJ et al (2023) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD007784.pub3","DOI":"10.1002\/14651858.CD007784.pub3"},{"key":"2423_CR24","doi-asserted-by":"publisher","unstructured":"Qin X, Dong H, Fang K, Lu F (2017) The effect of statins on renal outcomes in patients with diabetic kidney disease: a systematic review and meta-analysis. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.2901","DOI":"10.1002\/dmrr.2901"},{"key":"2423_CR25","doi-asserted-by":"publisher","unstructured":"Mach F et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2423_CR26","doi-asserted-by":"publisher","unstructured":"Polito L, Bortolotti M, Battelli MG, Bolognesi A (2022) Chronic kidney disease: which role for xanthine oxidoreductase activity and products? Pharmacol Res 184:106407. https:\/\/doi.org\/10.1016\/j.phrs.2022.106407","DOI":"10.1016\/j.phrs.2022.106407"},{"issue":"5","key":"2423_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000522248","volume":"47","author":"B Wu","year":"2022","unstructured":"Wu B et al (2022) The Effect of Allopurinol on renal outcomes in patients with Diabetic kidney disease: a systematic review and Meta-analysis. Kidney Blood Press Res 47(5):291\u2013299. https:\/\/doi.org\/10.1159\/000522248","journal-title":"Kidney Blood Press Res"},{"key":"2423_CR28","doi-asserted-by":"publisher","unstructured":"Pugh D, Gallacher PJ, Dhaun N (2019) Management of hypertension in chronic kidney disease. Drugs 79(4):365\u2013379. https:\/\/doi.org\/10.1007\/s40265-019-1064-1","DOI":"10.1007\/s40265-019-1064-1"},{"key":"2423_CR29","doi-asserted-by":"publisher","unstructured":"Mancia G et al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens 41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480","DOI":"10.1097\/HJH.0000000000003480"},{"key":"2423_CR30","doi-asserted-by":"publisher","unstructured":"Jamerson K et al (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359(23):2417\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa0806182","DOI":"10.1056\/NEJMoa0806182"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02423-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-024-02423-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02423-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:18:26Z","timestamp":1753186706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-024-02423-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2423"],"URL":"https:\/\/doi.org\/10.1007\/s00592-024-02423-w","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All subjects gave written informed consent for their participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}